Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Cash & Equivalents (2020 - 2025)

BioAtla (BCAB) has 6 years of Cash & Equivalents data on record, last reported at $8.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 85.28% year-over-year to $8.3 million; the TTM value through Sep 2025 reached $8.3 million, down 85.28%, while the annual FY2024 figure was $49.0 million, 56.0% down from the prior year.
  • Cash & Equivalents reached $8.3 million in Q3 2025 per BCAB's latest filing, down from $18.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $269.9 million in Q3 2021 and bottomed at $100000.0 in Q3 2023.
  • Average Cash & Equivalents over 5 years is $129.1 million, with a median of $140.1 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 112730.98% in 2021, then crashed 99.94% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $245.0 million in 2021, then fell by 27.29% to $178.1 million in 2022, then plummeted by 37.42% to $111.5 million in 2023, then tumbled by 56.0% to $49.0 million in 2024, then tumbled by 83.04% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $8.3 million in Q3 2025, $18.2 million in Q2 2025, and $32.4 million in Q1 2025.